BIOSENIC news, videos and press releases - Page 2
For more news please use our advanced search feature.
BIOSENIC - More news...
BIOSENIC - More news...
- BioSenic publishes new data on the mechanism of action of arsenic trioxide (ATO)
- BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population
- BioSenic SA: Information on the total number of voting rights and shares
- BioSenic announces initiation of coverage by Portzamparc and Gilbert Dupont
- BioSenic appoints Dr Carole Nicco as Chief Scientific Officer
- BioSenic SA : Information on the total number of voting rights and shares
- BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer
- BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)
- Bone Therapeutics SA: Transparency notification received from S.F.P.I/F.P.I.M
- Bone Therapeutics to regain worldwide rights to ALLOB
- Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022
- Bone Therapeutics SA: Information on the total number of voting rights and shares
- Bone Therapeutics reports half year 2022 results
- Bone Therapeutics SA: Information on the total number of voting rights and shares
- Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022
- Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic
- Bone Therapeutics SA: Information on the total number of voting rights and shares
- Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures
- Bone Therapeutics SA: Information on the total number of voting rights and shares
- Bone Therapeutics Provides First Quarter 2022 Business Update
- Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
- Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
- Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
- Bone Therapeutics announces 2021 full year results
- Bone Therapeutics provides fourth quarter 2021 business update and 2022 outlook
- Bone Therapeutics SA: Information on the total number of voting rights and shares
- Bone Therapeutics announces closing of private placement
- Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement
- Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB
- Bone Therapeutics Provides Third Quarter 2021 Business Update
